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Mononuclear Pd(II) and Pt(II) complexes with an α-N-heterocyclic 
thiosemicarbazone: cytotoxicity, solution behaviour and 
interaction versus proven models from the biological media 
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Two Pd(II) and Pt(II) complexes with two pyrrol-2-carbaldehyde N-p-chlorophenylthiosemicarbazone ligands are designed 
and characterized showing mononuclear structures. An important pharmacological property for both compounds is the 
high selectivity for tumor cells and a lack of activity in healthy cells. The Pd(II) compound shows higher antitumor activity 
and selectivity than the Pt(II) compound. Both complexes present a variety of biological interactions: with DNA models 
(pBR322 and CT DNA), proteins (lysozyme and RNase) and other biological targets like proteosome. Our results show that 
the Pd(II) complex is a more interesting candidate for potential anticancer therapies than the Pt(II) complex, and we 
provide new insight into the design and synthesis of palladium compounds as potential antitumor agents. 
Introduction 
Thiosemicarbazone ligands (TSCN) are molecules with an 
established history as pharmacological agents, not only for 
their biological properties but also because of their great 
capacity for binding with metals. Triapine® is a 
thiosemicarbazone containing an N-heterocyclic ring and is of 
special interest because of its multiple clinical trial studies1, 2. 
Triapine® is currently included in a Phase 2 of an ongoing 
clinical trial for the treatment of non-localized cervical cancer 
at the National Cancer Institute.3 The most accepted 
hypothesis regarding TSCN antitumoral action is based in their 
chelating properties, which indirectly lead to study 
ribonucleotide reductase (RR) as the mechanism through 
which these molecules work.4 RR is an iron-dependent enzyme 
that promotes the reduction of ribose to deoxyribose. Some 
TSCNs’ affect RR inhibition and lead to the blockage of the 
synthesis phase of the cell cycle and eventually to cell death by 
apoptosis.5 
α-N-heterocyclic thiosemicarbazones turned out to be the 
most potent inhibitors of RR so far,6 and the identification of 
its metal coordination was reported to afford more active 
species than free ligands.7 Recent studies have shown that the 
methylation of Triapine®results in a change of the mode of 
action, which might be associated with its possible interaction 
with copper caused by the balance of the intracellular copper 
concentration. However, these effects do not seem to be 
responsible for the increased cytotoxic activity of some 
derivatives into the nanomolar range.8 
Para-substituted phenyl thiosemicarbazones are another 
example of strong antitumor compounds and their metallation 
using palladium and platinum are reported to afford 
complexes that highly enhance the antitumor action of the 
ligands. The data from these complexes showed a good 
correlation of their cytotoxic activity with their structures and 
mode of action.9 By changing the structure of the complex, 
their interaction with DNA varies from cisplatin type of 
interaction to interstrand crosslinking.10, 11 Heterocyclic TSCN 
are good candidates not only to afford platinum and palladium 
complexes,12 but also complexes with some other metals such 
as copper13, 14 and ruthenium.15 The most remarkable results 
have been achieved so far with copper,16, 17 iron and gallium1 
bound to Triapine®. 
Following these results and trying to elucidate, if metal 
complexes from α-N-heterocyclic thiosemicarbazones can 
achieved more selectivity versus special tumor lines, we have 
developed a new series of metal complexes with pyrrol-2-
carbaldehyde 4N-p-chlorophenylthiosemicarbazone (LH2) 
where the metal can be Pd(II) and Pt(II). 
We seek not only selective and active compounds versus 
specific cancer cell lines such the human osteosarcoma MG-63 
cell line.18 We also search for compounds that might allow 
normal cell viability of non-tumoral cell lines “in vitro” (for 
example L929 fibroblast). In this work, we present new 
compounds and the studies of their cytotoxicity, structure and 
stability in solution, demonstrating their potential as antitumor 
drugs. The binding and/or affinity to biological models such 
two model proteins (lysozyme and RNase), proteasome and 
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DNA, indicates a different mode of action to the classical 
metallodrugs, such as cisplatin. 
Results and discussion 
Chemistry 
Scheme 1 shows the synthesis of the thiosemicarbazone, 
pyrrol-2-carbaldehyde 4N-p-chlorophenylthiosemicarbazone 
(LH2). The synthesis began with 
4N-p-chlorophenyl 
thiosemicarbazide preparation, using stoichiometric amounts 
of p-chlorophenyl isothiocyanate and hydrazine monohydrate. 
The procedure to synthesize thiosemicarbazones was reported 
in the fifties and proceeds by the condensation of the 
aldehyde and the corresponding thiosemicarbazide.19 This 
procedure has been used for obtaining a broad number of 
thiosemicarbazones derivatives12. The experimental section 
includes the detailed procedure used for the synthesis of LH2. 
The Pd(II) complex 1, was synthesized using Li2PdCl4, prepared 
in situ from palladium(II) chloride and lithium chloride (1:2) in 
MeOH,20 then reacted with the stoichiometric amount of LH2
at room temperature to afford complex 1.  
The low solubility of complex 1 allowed to obtain low 
concentrated DMSO solutions that easily led to single crystals 
suitable for X-ray diffraction structure resolution. We used 
crushed and vacuum dried single crystals samples for full 
characterization and biological assays. IR, NMR and analysis 
data are in agreement with the structure of the complex finally 
solved by X-Ray diffraction (Figure 1). 
Figure 1. X-Ray structure of complex 1 
The structure of complex 1 consists of discrete molecules that 
correspond to [Pd(LH)2]·2DMSO unit. The geometry around 
the metal ion is square planar being the palladium atom bound 
to the sulfur and azomethine nitrogen atoms of the two 
mutually trans, deprotonated thiosemicarbazone ligands. The 
asymmetric unit only contains one-half of the complex 1 
molecule, with the palladium atom located on a 
crystallographic inversion centre, together with one DMSO 
molecule. The distances and angles around the Pd atom are 
within the range expected for these kind of mononuclear21 and 
other polynuclear complexes published previously by our 
group of research10(Table 1). 
Table 1. Selected bond distances and angles for [Pd(LH)2]·2DMSO 
Bond distances (Å)  Bond distances (Å)    Bond angles (º) 
Pd1-N1 
Pd1-S1 
C1-N1 
C2-N3 
C5-N3 
2.023(3) 
2.2731(12) 
1.288(5) 
1.364(5) 
1.340(5) 
C6-N2 
C6-N4 
C6-S1 
C7-N4 
N1-N2 
1.296(5) 
1.357(5) 
1.736(4) 
1.410(5) 
1.415(4) 
N1-Pd1-N1 
N1-Pd1-S1 
S1-Pd1-S1 
180.0 
83.33(8) 
180.0 
The synthesis of the platinum complex, 2 was similar to the 
one used for complex 1, as shown in Scheme 1, but required 
the use of water to dissolve the starting material K2PtCl4. The 
characterization of complex 2 by the usual techniques 
indicated a general formula: [Pt(LH)2], similar to complex 1. 
Unfortunately, none of single crystals achieved were adequate 
for X-ray characterization. 
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Scheme 1 
The stability of both complexes was studied by 1H NMR (fresh 
sample and 24h) in DMSO-d6 (Figure SM1) and by UV in 
Trisbuffer:DMSO (95:5) (Figure SM2 and SM3). Complexes 1 
and 2 behaviour in solution is very similar. The UV spectra 
showed no significant changes (no shifts of the λmax and no 
new peaks) other than a small decrease in absorbance values 
after 24h. Both complexes’ (1 and 2) solutions are stable 
enough to be studied as potential metallodrugs within pH 
range = 6-8. Both complexes’ (1 and 2) solutions are stable 
enough to be studied as potential metallodrugs within pH 
range = 6-8. 
Cytotoxicity 
Following our expectations to achieve a novel drug with 
specific activity versus cancer cell lines, both compounds 1 and 
2 showed an antiproliferative activity values within 25-100 µM 
(table 2A) and 15-50 µM (Table 2B) for the following cell lines: 
Jurkat (human leukemia), MG-63 (human osteosarcoma) and 
A549 (human lung adenocarcinoma), remarkably none of the 
complexes showed such effect in normal mice fibroblast L929.  
Cisplatin showed a much higher cytotoxicity in this normal cell 
line phenotype (L929) compared with the new complexes 
cytotoxicity, and this particular effect enhances the potential 
value of complexes 1 and 2 as new metallodrugs in anticancer 
therapy. 
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The best candidate is the palladium derivative, complex 1, 
which showed a lower IC50 in leukemic and osteosarcoma cell 
lines than the platinum derivative, complex 2. The IC50 value of 
complex 1 in the lung cancer cell line A549 (see Table 2A, 60 
µM) is a more remarkable data than the platinum complex 
value (100 µM) and is similar to cisplatin (62µM). Moreover, 
after 72 h of incubation, the IC50 value of complex 1 in A549 
cells is 36 µM whilst for the platinum complex is 79 µM (see 
Table 2B).  
Table 2A. IC50 values of complex 1 and 2 in several cell lines after 48h. 
L929(µM) Jurkat(µM) A549(µM) MG-63(µM) 
1, Pd(LH)2 >100 47 ± 3 60 ± 3 34 ± 2 
2, Pt(LH)2 >100 63 ± 2 >100 56 ± 5 
cisplatin 43 ± 4 8 ± 1 62 ± 5 33 ± 3 
Table 2B. IC50 values of complex 1 and 2 in several cell lines after 72 h.  
L929(µM) Jurkat(µM) A549(µM) MG-63(µM) 
1, Pd(LH)2 86 ± 4 17 ± 5 36 ± 3 20 ± 4 
2, Pt(LH)2 81 ± 3 33 ± 4 79 ± 4 32 ± 3 
cisplatin 26 ± 3 4 ± 1 29 ± 5 17 ± 3 
Table 2C shows the higher selectivity of compound 1 for A549 
and MG-63 cells in comparison with compound 2 and cisplatin. 
The SI values are 2.46, 1.02, 0.90 (A549 cells) and 4.3, 2.3 and 
1.5 (MG-63 cells) for compound 1, 2 and cisplatin, respectively. 
Nevertheless, cisplatin showed a better correlation of SI on 
Jurkat cells than compound 1 and 2. 
Table 2C. SI (Selectivity Index) values of complexes 1, 2 and cisplatin in several cell lines 
after 72h 
Jurkat A549 MG-63 
1, Pd(LH)2 5 2.46 4.3 
2, Pt(LH)2 2. 4 1.02 2.5 
cisplatin 6.5 0.90 1.5 
SI (Selectivity index) is a comparison of the amount of a therapeutic agent that 
causes the therapeutic effect (on tumor cells) and amount that causes toxicity 
(using normal cells) 
To our knowledge, there are very few examples in the 
references where the palladium thiosemicarbazone derivative 
showed better cytotoxicity than the platinum analogue.22-24 In 
fact, this kind of response should not be that unusual in 
chelate complexes, based in the higher kinetic lability of the 
Pd(II) complexes25, which should endow the complex with a 
better interaction potential with DNA or other biological 
molecules usually overexpressed in the cancer cells. 
Reactivity versus biological molecules 
Affinity of the complexes for the model CT DNA 
Covalent binding with DNA is the reported mode of action of 
cisplatin like metallodrugs, via aquation of the leaving 
groups.26 However, there are other antitumor active metal 
complexes keeping their ligands and their structure integrity in 
physiological solution, and those can interact with DNA by 
many different mechanism.27, 28 Examples of such mechanism 
are: cleavage of the DNA-helix, non-covalent interaction, the 
intercalation by stacking in between the DNA-bases, 
electrostatic, hydrophobic or hydrogen bonding from different 
groups and substituents with the DNA and even van der Waals 
forces.12, 29, 30
The affinity of both complexes for CT DNA was evaluated using 
UV spectroscopy titrations, as a preliminary step to determine 
information concerning their possible targets and provide 
information about the mechanism. The typical β-form of DNA 
exhibit a characteristic π-π∗ band at 260nm, which is sensitive 
to structural changes in the macromolecule and can become 
hyperchromic (increase in absorption of the DNA band at 260 
nm) by perturbation resulting from non-covalent external 
interaction.31 
First, the UV spectra of a CT DNA solution (3.2 × 10−5 M) were 
monitored using increasing concentration of the complexes 1-
2 (following different r values in table 3 and figure SM4)), 
allowing the sample to react for 10 minutes.  The binding to CT 
DNA showed an increasing effect in the 260nm band; typically 
described for a hyperchromic effect (Table 3 collects the 
values). All of these data might indicate interaction of the 
complexes with CT-DNA that could be interpreted as an 
external non-covalent interaction, and no bathochromic effect 
is detected.31 
Table 3. UV/Vis absorption data of complex 1 and 2 with CT DNA and their DNA-binding 
constants (Kb). 
ar=1,25=[complex]/[DNA]; b (%) = 100(ADNAbound-ADNA free)/ADNA free 
Secondly, the UV spectra of increasing concentration of CT 
DNA solution (3.2 × 10−5 M) were monitored using a fixed 
concentration of the complexes 1-2 (2.5 × 10−6M, see figure 
SM5), allowing the sample to react for 10 minutes.  The DNA-
binding constants (Kb) of complexes 1 and 2 (Table 2) were 
determined by the plots [DNA]/(εa-εf) versus [DNA] (Fig. SM5) 
using the Wolfe-Shimer equation 32. In brief, the Kb constants 
of the complexes 1 and 2 are comparable with those observed 
for classical groove binders (Table 3), such a as Hoechst 32258 
with a 4.6•105 M-1 with A3T3 duplex 33.  
These values, recorded in the first 10 minutes of reaction, 
seemed to indicate that the reactivity of these compounds 
could be interpreted as having a good affinity for CT DNA base 
pairs in a non-covalent binding mode of action. The reactivity 
observed is quite different to cisplatin, which is as a covalent 
binder reported to produce two effects: hyperchromic and 
bathochromic after 7h or reaction.31 
Interaction of the complexes with the plasmid DNA supercoiled 
pBR322 
Based in the best cytotoxicity values, we selected complex 1 to 
evaluate its interaction with a more specific model of DNA. We 
performed a study of its interaction with a supercoiled DNA 
pBR322 (containing two isoforms) used as a model of the 
Band (nm); Aa Hyperchromism %b Kb (M-1) 
CT-DNA 260 ; 021 - - 
Complex 1 265; 0.44 37 2.55·105 
Complex 2 266; 0.32 34 3.99 ·105 
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secondary structure of DNA. Cisplatin binds covalently to DNA 
and also to pBR322 producing a delay in its closed circular 
form (cc) and slowing down the open circular form (oc) 
because of its unwinding. 26, 34 
Complex 1 was assayed at different ri concentrations after 
24h.The electrophoresis results showed that complex 1 did not 
seem to alter the electrophoretic mobility of the plasmid, but 
we could barely detect a blur band in between the oc and ccc 
forms (data not shown). Several repetitions did not improve 
the visibility of such band that is why we allowed a longer time 
of reaction. After 48h (Figure 2), we could clearly detect a new 
band in lines 3 to 6 possibly caused by a nicked in one of the 
pBR322 form (marker and pBR322 control are in lines 1 and 2 
respectively for better comparison). This assay manifests that 
complex 1 is able to produce a new band corresponding 
possibly to a new fragment. Complex 1 interaction with 
pBR322 showed a different mode of action compared to 
cisplatin. 
Figure 2. Electrophoresis in agarose gel of pBR322 plasmid treated with complex 1.  ri: 
metal complex:DNA base pairs. Line1: marker (DNA 1kb ladder) Line 2: C: control of 
incubated DNA plasmid pBR322, line 3 to 6: complex 1: Plasmid DNA incubated at ri = 
0.01 to 0.1. 
Genotoxicity study 
The genotoxic effects of complexes 1 and 2 were investigated 
through the induction of DNA damage. The single cell gel 
electrophoresis (SCGE) or comet assay is an important test 
used for the investigation of genotoxicity. It detects single and 
double strand DNA breaks. Sites where excision and repairs 
have occurred are detected under alkaline conditions.35 For 
both complexes, we evaluated the tail moment parameter, 
which is defined as the tail length × DNA amount in the tail. 
The distance of DNA migration is used to measure the extent 
of DNA damage. However, if DNA damage is relatively high, 
the tail increases in fluorescent staining intensity but not in 
length.36 Thus, for these reasons it is useful to use the tail 
moment as a genotoxic endpoint. As it is shown in Fig. 3A, 
complex 1 produced a significant genotoxic effect in Jurkat 
cells from 2.5 to 5 µM with a dose-response effects (p < 
0.001). From 10 μM the genotoxic effect is less pronounced. 
The decrease in DNA damage as the complex concentration 
increases may be due to overt cytotoxicity exerted on this cell 
line. Moreover, the genotoxic effects of complex 1 are higher 
than bleomycin (positive control) showing following tail 
moment values: 16 ± 0.6, 28 ± 0.4 and 13 ± 0.6 for complex 1 
and bleomycin, respectively. 
In addition, complex 2 exert genotoxic effects showing a lesser 
effect than complex 1. Besides, both complexes did not exert 
genotoxic effects on normal L929 fibroblast from 2.5 to 10 μM 
whilst cisplatin induced the break of cellular DNA in the same 
range of concentrations (see Figure 3B and Figure SM8). These 
results may explain the low cytotoxicity of both compounds on 
L929 cells in comparison with deleterious effects of cisplatin 
(see Table 2). In this sense, cisplatin has a well-known 
mechanism of interaction with DNA. 
Altogether, these results suggest that the genotoxic effects of 
complex 1 are higher than complex 2 in Jurkat cells, leading to 
a positive result in the comet assay and in agreement with the 
result observed in Figure 2. 
Figure 3. Genotoxicity of complexes 1 and 2 on Jurkat cells (A) and L929 cells (B) 
determined by SCGE (comet assay). DNA damage was evaluated by the tail moment. 
After incubation with both compound for 48 h, cells were lysed and DNA fragments 
were processed by electrophoresis. After that, the nuclei were stained and analyzed. 
Results are expressed as mean ± SEM (n = 150), *p < 0.001. BLM stands for bleomycin 
(10 µg/mL) used as a positive control. 
Proteins 
The binding of complex 1 with Lysozyme and RNase was 
evaluated with UV spectroscopy as described in the 
experimental part. The k’ was calculated as a pseudo first 
order reaction (k’RNase: and k’Lys: 1.91x10
-4s-1 and 1.33x10-4s-1) 
using the 3:1 stoichiometry (metal to protein) as the result 
were equal using the stoichiometry 10:1(metal to protein) 
(Figure SM6 and SM7).  The rate constant of complex 1 with 
Lysozyme and RNase give us an estimation of the compatibility 
and reactivity of complex 1 in the presence of representative 
proteins of cellular media. We have used cisplatin as a control, 
and its values with lysozyme (1.98·10-4 s-1) and RNase (1.88·10-
4 s-1) are in agreement with those found with other models 
such as albumin, transferrin, and cytochrome c.37, 38 Complex 
1’s values are within the range found for cisplatin.
Interaction of the complexes with a proteasome target 
In order to shed light on the mechanism of action for these 
complexes, and based on the lower reactivity with CT DNA, we 
evaluate a more specific target: proteasome. The ubiquitin-
mediated proteasomal proteolysis is the main mechanism of 
degradation of proteins in human cells.39 The 20S proteasome, 
which is the proteolytic core of the multicatalytic 26S 
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proteasome complex, has several proteolytic activities, 
including chymotrypsin-like, trypsin-like… etc.40 
Nevertheless, it has been shown that only inhibition of the 
chymotrypsin-like activity is tightly associated with induction 
of tumor cell death programs.41 Proteasome inhibitors cause a 
buildup of unwanted proteins in the cell, inducing cell death 
rapidly and selectively, TSCNs derivatives has been also 
reported to be inhibitors of this target.42 
We performed a cell-free proteasome activity assay in the 
presence of each of these compounds at different 
concentrations (2.5 to 100 µM). As it can be seen in the Table 
4, the gradual decrease in the fluorescence indicates the 
proteasome inhibition ability. Complexes 1 and 2  inhibits he 
chymotrypsin-like activity of purified 20S proteasome with 
different potencies since complex 2 was found to be the most 
potent inhibitor (see Table 4). 
Table 4. Proteasome (chymotrypsin-like activity) inhibition percentage of complexes 1 
and 2  
Concentration (µM) 1 (% Basal ± SD) 2 (% Basal ± SD) 
2.5 97 ± 2 95 ± 1 
5 94 ± 4 93 ± 1 
10 73 ± 3 79 ± 3 
25 73 ± 4 55 ± 4 
50 69 ± 1 44 ± 2 
100 51 ± 2 24 ± 2 
In this order, Tundo and col. showed that cisplatin induces a 
dose dependent inhibition of the three activities of 
proteasome, at least over the concentration range 
investigated (2.5-15 µM). The described behaviors clearly 
demonstrate that cisplatin significantly affects the enzymatic 
properties of proteasome in vitro.43  
On the other hand, we confirm the inhibitory effects of 
complex 1 and 2 on proteasome activity, we performed a cell 
proteasome activity experiments using Jurkat cells in the 
presence of 100 µM of complexes 1 and 2. Proteasomal 
activity was inhibited to similar levels by both compounds. As 
it can be seen that the complex 1 reduced the proteasome 
activity in 28% whilst the complex 2 decreased the proteasome 
activity in 23% showing a similar proteasome inhibition effects. 
ROS Production 
Oxidative stress is one of the main factors reported that trigger 
the deleterious actions of metal-based compounds.44, 45  
For a better understanding of the possible mechanism 
involved in the cytotoxicity of both complexes in cancer cell 
lines, we evaluated the effect of complexes 1 and 2 on 
oxidative stress through the oxidation of the probe DHR-123. 
DHR-123 is a mitochondria-associated probe that selectively 
reacts with hydrogen peroxide.46 Incubation of Jurkat cells 
with the complex 1 caused an increase in the production of 
ROS. At 10 µM, complex 1 increased ROS production after 48 h 
generated 182% of ROS level over basal (p<0.01) whereas at 
2,5 and 5 µM no production of ROS over the basal level could 
be observed (p<0.01). Moreover, the complex 2 does not 
exhibit a ROS production in the range of concentrations tested 
(2.5-25 µM) (see Figure SM9). 
Apoptosis 
Apoptosis is a physiological process of cell death enhanced in 
the presence of injurious agents. As a consequence, a genetic 
program that leads to cell death is activated. Apoptosis is 
characterized by some morphological changes in the nucleus 
and the cytoplasm. Because of this, apoptosis can be assessed 
by using several characteristic features of programmed cell 
death. Independently of the cell type and the nature of the 
harmful agent, the externalization of phosphatidylserine is 
always present in the earlier apoptotic events. Annexin V–FITC 
is a fluorescent probe with high affinity for phosphatidylserine, 
allowing its determination by fluorescence assays. Figure 4 
depicted the flow cytometry results of the apoptotic process in 
the presence of complex 1 and 2 (10, 25, 50 and 100 µM) after 
48 h of incubation in Jurkat cells. 
Figure 4. Induction of apoptosis in Jurkat cells. The panels show the cell distribution 
revealed by the intensity of PI-derived fluorescence and annexin V positive, in 
untreated cell cultures (Control) and cultures treated for 48 h in the presence of 
complex 1 and 2 (10, 25, 50 and 100 µM). 
Table 5 displays the quantification of early and late stages of 
apoptosis obtained by flow cytometry in Jurkat cells. This table 
shows that the control cultures showed 0.7% of early 
apoptotic cells and 2.6 % of late apoptotic cells. These results 
changed when incubated the cells with 10, 25 and 50 µM of 
complex 1 and 2, showing an increase in the early and late 
apoptotic cellular fraction. 
Complex 1 resulted in approximately 4.3% and 11.1 % early 
apoptotic cells (annexin V positive) at 25 µM and 50 µM, 
respectively, whilst complex 2 did not show any changes in 
early apoptotic fractions over basal at 10, 25 and 50 µM. 
Nevertheless, both compounds increased late apoptotic 
fractions, complex 1 produced 15.4% and 45.2 % at 25 µM and 
50 µM whilst complex 2 resulted in 5.6 % and 13.9 % at the 
same concentrations. 
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As can be seen, the percentages of apoptotic and 
apoptotic/necrotic cells increased with the concentration of 
both complexes. These results are in accordance with the 
viability assays, confirming that the deleterious action of 
complex 1 are higher than complex 2 
Table5. Percentage of apoptotic cells treated with complexes 1 and 2.  
Annexin V+/PI- Annexin V+/PI+ 
Concentration(µM)  1 (%) 2 (%)  1 (%) 2 (%) 
0  0.7  0.7  2.6  2.6  
10  0.9  1  3.1  3.8  
25  4.3  0.3  15.4  5.6  
50  11.1  0.2  45.2  13.9  
On the other hand, caspases (cysteine-requiring aspartate 
proteases) are a family of proteases that mediate cell death 
and are important to the process of apoptosis. Caspase 3 is 
one of the critical members of this family. It is an effector 
caspase that cleaves most of the caspase-related substrates 
involved in apoptosis regulation.47  
Figure 5. Induction of apoptosis in Jurkat cells. A) the panels show the cell distribution 
with SSC and caspase-3 levels, in untreated cell cultures (Control) and cultures treated 
for 48 h in the presence of compound 1 and 2 (10, 25 and 50 µM). B) caspase 3 
activation versus complex 1 and 2 concentration graph 
In Figure 5, it can be seen that after 48 h of incubation of the 
cells with complex 1 and complex 2, caspase 3 is activated at 
25 and 50 µM for compound 1 and only at 50 µM for 
compound 2 (p<0.01), demonstrating that the apoptotic action 
of both complexes is in agreement with the annexin V assay. 
The activation of caspase 3 is a good marker to confirm the 
annexin V results for the detection of late apoptosis. 
Experimental 
Materials and methods 
In general, solvents and starting materials were purchased 
from the commercial companies: VWR and Aldrich –Sigma. In 
particular, the proteasome was purchased from Merck and 
plasmid pBR322 from GenCust.  
Tissue culture materials were purchased from Corning, 
Dulbecco´ s Modified Eagles Medium (DMEM), TrypLETM from 
Gibco and fetal bovine serum (FBS) from Internegocios SA. 
Dihydrorhodamine 123 (DHR) was purchased from Molecular 
Probes (Eugene, OR). Syber Green and Low melting point 
agarose were purchased from Invitrogen Corporation. 
Mono-dimensional 13C-NMR and 1H-NMR experiments were 
performed in DMSO-d6 and D2O using a Bruker AMX-300 (300
MHz) spectrometer at room temperature (25 °C). Elemental 
analyses were performed on a Perkin Elmer 2400 Series II 
microanalyzer. Fast atom bombardment (FAB) mass spectrum 
(MS) was performed on a VG AutoSpec spectrometer. IR was 
performed in a Perkin Elmer Model 283 spectrophotometer 
with an ATR accessory (Miracle Single Reflection Horizontal). 
UV-Visible in a Thermo Fisher Scientific Evolution 260 Bio 
spectrophotometer. 
Chemistry 
Pyrrol-2-carboxaldehyde 
4
N-p-chlorophenilthiosemicarbazone LH2 
4
N-p-chlorophenylthiosemicarbazide preparation was 
performed following a procedure used for similar 
compounds48: 20 mL of an ethanolic solution of hydrazine 
monohydrate (0.25 g, 5 mmol) was added dropwise and with 
constant stirring to a 20mL of a cold ethanol solution of p-
chlorophenyl isothiocyanate (0.85 g, 5 mmol). The solution 
was allowed to stand until a white solid precipitation formed. 
The final compound was filtered off, washed with cold ethanol 
and diethyl ether and dried in vacuo. Yield 41% (0.41 g). The 
compound was achieved previously and characterized by X-
ray, but there are no reports in the reference of further 
characterization of this compound using the usual 
spectroscopic and analytical techniques. The characterization 
is included as follows: 
Mp 180 ºC. Elemental analysis found, C, 41.70; H, 4.15; N, 
20.80; S, 16.11; C12H11N4SCl requires C, 41.70; H, 4.00, N, 
20.85; S, 15.85 %. IR (KBr pellet): υ/cm-1 3293, 3178 (s, NH); 
1635 (s, NH2); 820 (w, CS-thioamide IV). 
1H NMR (d6-DMSO,
ppm), δ=9.19 [s, NH, 1H]; 7.70, 7,67 (d, J = 9.0 Hz, CH, 2H); 
7.34; 7.31 (d, J = 9.0 Hz, CH, 2H). 
Thought the procedure was first reported in the fifties19 later 
on slightly changed for α-N- heterocycles thiosemicarbazones 
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and it proceeds as follows49: p-chlorophenylthiosemicarbazide 
LH2 (0.403 g, 2 mmol) was dissolved in 20 mL of ethanol  and 5 
mL of warm water at 40ºC. The clear solution was added 
dropwise to an ethanolic solution (10 mL) of pyrrol-
2carboxaldehyde (0.19 g, 2 mmol). The reaction was heated to 
reflux for 5h (~78 ºC), afterwards the reaction was taken to the 
rotavapor and concentrated to half of the volume until a 
yellow solid precipitates which was isolated by filtration, 
washed with ethanol and dried.  
Yield: 51% (0.284 g). Mp 195 °C (decomposes). Elemental 
analysis found, C, 51.20; H, 4.00; N, 19.70; S, 11.80; 
C12H11N4SCl requires C, 51.70; H, 3.95, N, 20.10; S, 11.50 %. MS 
(FAB+ with mNBA: nitrobenzyl alcohol matrix) m/z 279 for 
[H2L+H]
+. IR (KBr pellet): υ/cm-1 3291, 3225, 3151 (m, NH);
1609 (s, CN); 820 (w, CS-thioamide IV). 1H NMR (d6-DMSO, 
ppm), δ=11.78 [s, 3NH, 1H]; 11.52 [s, 2NH, 1H]; 10.06 [s, 4NH, 
1H]; 7.99 [s, 1CH, 1H]; 7.68, 7,65 (d, J = 9.3 Hz, 9CH, 11CH, 2H); 
7.47; 7.44 (d, J = 9.3 Hz, 8CH, 12CH, 2H); 7.09 [s, 5CH, 1H]; 6.48 
[s, 4CH, 1H]; 6.15 [s, 3CH, 1H]. 13C NMR (d6-DMSO, ppm), 
δ=176.08 (C6); 139.29 (C7); 135.91 (C2); 130.38 (C1); 129.44 
(C9, C11); 128.66 (C10); 127.97 (C8, C12); 123.57 (C5); 115.19 
(C3); 110.85 (C4). UV/vis (DMSO UV/vis (DMSO): λ/nm 287 (IL 
π−π∗), 347 (IL n −π∗). 
Complexes 1 and 2 
Complex 1, [Pd(LH)2]. A solution of LH2 (0.143 g; 0.50 mmol) in 
methanol (MeOH) (20 mL) was added dropwise to a solution of 
Li2PdCl4, prepared in situ, from PdCl2 (0.044 g; 0.25 mmol) and 
LiCl (0.004 g; 1 mmol) in methanol (20 mL). The mixture was 
kept stirring at room temperature for 2 hours. The final solid 
was isolated by filtration. Then washed with hot MeOH, dried 
under vacuum into a dry oven at 60°C. 0,142 g (yield: 86%).  
Yield: 86% (0.142 g). Mp >250 °C. Elemental analysis found, C, 
40.15; H, 3.30; N, 15.35; S, 8.90; C24H20N8S2Cl2Pd•3H2O 
requires C, 40.25; H, 3.65, N, 15.65; S, 8.95 %. MS (FAB+ with 
mNBA: nitrobenzyl alcohol matrix) m/z 663 for [H2L+H]
+/[M]+.
IR (KBr pellet): υ/cm-1 3228 (m, NH); 1598 (s, CN); 827 (w, CS-
thioamide IV). 1H NMR (d6-DMSO, ppm), δ=11.54 [s, 3NH, 1H]; 
9.48 [s, 4NH, 1H]; 7.49 [s, 1CH, 1H]; 7.42-7,32 [m, 8CH, 9CH, 
11CH, 12CH, 4H]; 7.17 [s, 5CH, 1H]; 6.91 [s, 4CH, 1H]; 6.26 [s, 
3CH, 1H]; 13C NMR (d6-DMSO, ppm), δ=169.44 (C6); 146.87 
(C7); 140.28 (C2); 129.19 (C9, C11); 129.06 (C1); 127.37 (C10); 
123.14 (C8, C12); 12213 (C5); 120.21(C3); 111.18 (C4). λ/nm 
270 (IL π−π∗), 389 (CT Metal-L). Single crystals, suitable for X-
ray diffraction analysis, grown in a NMR tube from the d6-
DMSO solution used for NMR experiments.  
Complex 2, [Pt(LH)2]. 5mL of an aqueous solution of K2PtCl4 
(0.104 g, 0.25 mmol) was added dropwise to a methanolic 
solution (20 mL) of LH2 (0.140 g, 0.5 mmol). The mixture was 
stirred at room temperature during 5h. The final solid was 
filtered, washed with hot methanol and dried under vacuum. 
Yield: 58% (0.187 g). Mp >250 °C. Elemental analysis found, C, 
36.30; H, 3.05; N, 13.80; S, 8.00; C24H20N8S2Cl2Pt•2H2O 
requires C, 36.65; H, 3.05, N, 14.25; S, 8.15 %. MS (FAB+ with 
mNBA: nitrobenzyl alcohol matrix) m/z 751 for [H2L+H]
+.  IR
(KBr pellet): υ/cm-1 3226 (m, NH); 1608 (s, CN); 827 (w, CS-
thioamide IV). 1H NMR (d6-DMSO, ppm), δ=11.57 [s, 3NH, 1H]; 
9.61 [s, 4NH, 1H]; 7.46 [s, 1CH, 1H]; 7.35-7,25 [m, 8CH, 9CH, 
11CH, 12CH, 4H]; 7.07 [s, 5CH, 1H]; 6.50 [s, 4CH, 1H]; 6.16 [s, 
3CH, 1H]; 13C NMR (d6-DMSO, ppm), δ=175.15 (C6); 138.41 
(C7); 135.01 (C2); 129.44 (C1); 128.52 (C9, C11); 127.76 (C10); 
127.10 (C8, C12); 122.69 (C5); 114.29 (C3); 109.93 (C4). 
(DMSO): λ/nm 266(IL π−π∗), 355(CT Metal-L). 
Stability studies by UV and NMR 
Complexes 1 and 2 have been monitored from fresh to 24h in 
solution where the pH was adjusted to the physiological range, 
using the appropriate buffer solutions (Tris-HCl 0.5M Tris Base 
pH:7.6). 
Crystallography 
Data were collected on a Bruker Kappa Apex II diffractometer. 
A summary of the crystal data, experimental details and 
refinement results is listed in Table 6. The software package 
SHELXTL was used for space group determination, structure 
solution, and refinement.50 The structure was solved by direct 
methods, completed with difference Fourier syntheses, and 
refined with anisotropic displacement parameters.  
Table 6. Crystal and refinement data for [Pd(LH)2)]·2DMSO. 
[Pd(LH)2]·2DMSO 
Chemical formula C228H32Cl2N8O2PdS4 
Formula weight 409.08 g/mol 
Temperature 296(2) K 
Wavelength 0.71073 Å 
Crystal size 0.050 x 0.060 x 0.190 mm 
Crystal habit orange needle 
Crystal system monoclinic 
Space group P 1 21/c 1 
Unit cell dimensions 
a = 14.627(4) Å 
b= 5.7150(18) Å 
c = 20.939(7) Å  
α = 90º 
β = 4.995(10)º 
γ = 90º 
Volume 1743.7(9) Å3 
Z 2 
Density (calculated) 1.558 g/cm3
Absorption coefficient 0.964 mm-1 
Theta range for data 
collection 
1.95 to 25.37° 
Index ranges -17<=h<=17; -6<=k<=6; -25<=l<=25 
Reflections collected 26868 
Independent reflections 3189 [R(int) = 0.0538] 
Coverage of independent 
reflections 
99.9% 
Data / restraints / 
parameters 
3189 / 0 / 207 
Goodness-of-fit on F2 1.083 
Final R indices 
I > 2σ(I): R1 = 0.0403, wR2= 0.1064 
all data :  R1 = 0.0682, wR2 = 0.1297 
Largest diff. peak and hole 0.700 and -0.665 e Å3
Biology 
Cell line and growth conditions 
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MG-63 human osteosarcoma cells, A549 human lung 
adenocarcinoma cells and L929 mouse fibroblasts were grown 
in DMEM containing 10 % FBS, 100 U/mL penicillin and 100 
μg/mL streptomycin at 37ºC in 5% CO2 atmosphere. Cells were 
seeded in a 75 cm2 flask and when 70-80 % of confluence was 
reached, cells were subcultured using 1mL of TrypLE TM per 25 
cm2 flask. For experiments, cells were grown in multi-well 
plates. When cells reached the desired confluence, the 
monolayers were washed with DMEM and were incubated 
under different conditions according to the experiments. On 
the other hand, Jurkat cells (acute T cell leukemia) were grown 
in DMEM containing 10 % FBS, 100 U/mL penicillin and 100 
μg/mL streptomycin at 37ºC in 5% CO2 atmosphere. For 
experiments, cells were grown in multi-well plates according 
to the experiments. 
Cytotoxicity by MTT assay 
The MTT assay was performed according to Mosmann et al.51  
Briefly, cells were seeded in a 96-multiwell dish, allowed to 
attach for 24 h and treated with different concentrations of 
complex 1 and 2 at 37 °C for 48 and 72 h. After that, the 
medium was changed and the cells were incubated with 0.5 
mg/mL MTT under normal culture conditions for 3 h. Cell 
viability was marked by the conversion of the tetrazolium salt 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-
bromide) to a coloured formazan by mitochondrial 
dehydrogenases. Colour development was measured 
spectrophotometrically in a Microplate Reader (7530, 
Cambridge technology, Inc, USA) at 570 nm after cell lysis in 
DMSO (100 μL/well). Cell viability was plotted as the 
percentage of the control value. 
DNA and protein interaction 
Sample preparation 
In order to evaluate the biological behaviour of complexes 1-2, 
the compounds were initially dissolved in DMSO (5 mM). For 
all experiments, the desired concentration of complexes was 
achieved by dilution of the stock DMSO solution with aqueous 
buffer. All the solutions and buffers were previously tempered 
to 37 ºC. Afterward, the fresh prepared complexes solutions 
were mixed at 37 ºC with the aqueous buffer DNA/model 
protein solutions in a thermoshaker. The studies never 
exceeded 1% DMSO (v/v) in the final solution. Control 
experiments with DMSO were performed and no changes in 
the spectra of the model proteins or CT DNA were observed.  
UV/Vis titration experiments  
To investigate the potential binding ability of complexes 1-2 
with DNA spectrophotometric titrations (240-800nm) were 
performed at room temperature by: a) keeping constant the 
CT-DNA concentration (3.2 × 10−5 M) while varying the 
concentration of each complex (0-500 μM) and monitoring the 
changes in the typical absorbance of CT-DNA at 260 nm after 
equilibration (10 min. At 37ºC), b) keeping constant the 
complex concentration (2.5 × 10−6 M), varying the 
concentration of CT-DNA (0–500 μM) and monitoring the 
changes in the absorbance of one characteristic charge 
transfer band of the complex after equilibration (10 min. At 
37ºC). The first assay was used to estimate the nature of the 
supramolecular interactions while the latter assay was used to 
determine the DNA-binding constant of the complexes, Kb (in 
M-1) using the Wolfe-Shimer equation:32 
DNA
ε − ε	
=
DNA
 − 
+
1
( − )
where [DNA] is the concentration of the nucleic acid in base 
pairs, εa is the apparent absorption coefficient obtained by 
calculating Aobs/[compound], and εf and εb are the absorption 
coefficients of the free and the fully bound compound, 
respectively.  
Agarose gel electrophoresis  
Complex 1 was incubated at 37ºC with a concentration of 
0.0625μg/μL of pBR322 plasmid DNA, at different 
concentrations expressed as ri= Complex: DNA(base pair) ratio. 
The ri used is from 0.01 to 0.2, in a total volume of 20µL.  
After an incubation period of 24 and 48 h, the mobility of the 
complex treated pBR322 samples was analyzed by gel 
electrophoresis at 70 V/cm in Tris-acetate/EDTA buffer. A 
control of pBR322 was also incubated, and load of a 1kb 
ladder5mL was also loaded in lane 1 of the gel.  The gel was 
stained with an ethidium bromide aqueous solution and DNA 
bands were visualized with a UV-transilluminator. pBR322 was 
purchased from GenCust and the 1kb ladder from Aldrich-
sigma (D0428). 
Single cell gel electrophoresis (SCGE) assay 
For the detection of DNA strand breaks the single cell gel 
electrophoresis (‘comet’) assay was used in the alkaline 
version, based on the method of Singh et al.52 with minor 
modifications. Under alkaline conditions, DNA loops containing 
breaks lose supercoiling, unwind and are released from the 
nuclei and form a ‘comet-tail’ by gel electrophoresis. For this 
experiment, 2 × 104 cells were seeded in a twelve-well plate; 
24 h later the cells were incubated with various concentrations 
of the complexes. After treatment, cells were suspended in 
0.5% low melting point agarose and immediately poured onto 
glass microscope slides. Slides were immersed in an ice-cold 
prepared lysis solution at darkness for 1 h (4 °C) in order to 
lyse the cells, remove cellular proteins and to permit DNA 
unfolding. Immediately after this, slides were put in a 
horizontal electrophoresis tank containing 1 mM Na2EDTA, 0.3 
M NaOH (pH 12.7) and then electrophoresis was performed 
for 30 min at 25 V (4 °C). Afterwards, slides were neutralized 
and stained with Syber Green. Analysis of the slides was 
performed in an Olympus BX50 fluorescence microscope. 
Cellular images were acquired with a Leica IM50 Image 
Manager (Imagic Bildverarbeitung AG). A total of 50 randomly 
captured cells per experimental point of each experiment was 
used to determine the tail moment (the product of tail length 
by tail DNA percentage) using a free comet scoring software 
(Comet Score version 1.5). Two parallel slides were performed 
for each experimental point. Independent experiments were 
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repeated twice. A pulse of 20 minutes of 10 μg mL−1 bleomycin 
just before the cells were harvested was employed as the 
positive control. 
UV/Vis kinetics experiments 
To investigate the interaction of complex 1 with plasma 
proteins, electronic spectra of the protein models, HEWL (hen 
egg white lysozyme) and RNase A at 10−5 M were recorded 
(monitoring the typical absorbance of proteins at 280 nm) 
before and after the addition of complex 1 at a stoichiometric 
ratio of 3:1 (metal to protein) for 24 h at R.T. The binding 
affinity constants were calculated as a pseudo first order based 
on the equal results obtained for stoichiometry: 10:1 and 3:1 
for both cases.53 
Proteasome activity assay 
Proteasomal inhibition by complexes 1-2 was assayed using 
the 20S Proteasome Activity Assay Kit from Millipore. To 
determine whether both compounds inhibits proteasome 
function directly, the provided 20S proteasome was diluted 
1:60 in 100µl assay buffer and incubated according to the 
manufacturer’s instructions with the suc-LLVY-AMC substrate 
and the indicated concentrations of complexes 1-2 for 2 h at 
37°C. Fluoresence at 460 nm was read using a FluoSTAR 
OPTIMA microplate reader. 
Moreover, Jurkat whole-cell extract (8 μg) was incubated with 
10 μmol/L chymotrypsin-like-substrate (Suc-LLVY-AMC) in 100 
μL assay buffer [50 mmol/L Tris-HCl (pH 7.5)] in the presence 
of both compounds (100 μM each) or solvent DMSO as 
control. After a 2 h incubation at 37° C, production of 
hydrolyzed AMC groups was measured using a 
spectrofluorophotometer shimadzu RF-6000 with an excitation 
filter of 365 nm and an emission filter of 460 nm. 
Determination of Reactive Oxygen Species (ROS) Production 
Oxidative stress in Jurkat cells was evaluated by measurement 
of intracellular production of reactive oxygen species (ROS) 
after incubation of the cells with different concentrations (2.5-
25 µM) of the complex 1 in water (from 20 mM of stock 
solution in DMSO) during 48 h at 37 °C. ROS generation was 
determined by oxidation of DHR-123 to rhodamine by 
spectrofluorescence as we have previously described54.  
Measurements of externatization of phosphatidylserine by 
annexin V-FITC/PI staining 
Cells in early and late stages of apoptosis were detected with 
annexin V–FITC and PI staining. Cells were treated with 
different concentrations of compound 1 and 2 and were 
incubated for 48 h prior to analysis. Cells were analyzed using 
a BD FACS Calibur™ flow cytometer and FlowJo 7.6 software. 
For each analysis, 10,000 counts, gated on a forward scatter 
versus side scatter dot plot, were recorded. Four 
subpopulations were defined in the dot plot: the undamaged 
vital (annexin V negative/PI negative), the vital mechanically 
damaged (annexin V negative/PI positive), the apoptotic 
(annexin V positive/PI negative), and the secondary necrotic 
(annexin V positive/PI positive) subpopulations. 
Caspase 3 assay: 
The determination of caspase 3, one of the main effector 
caspases, was conducted with a commercial kit (Pharmingen 
TM caspase 3 assay kit, BD) following the recommendation of 
the manufacturer. The cells (10,000 events) were analyzed 
using a BD FACS Calibur™ flow cytometer and FlowJo 7.6 
software. 
Conclusions 
The synthesis of complexes using Palladium and Platinum as 
metals with a heterocyclic thiosemicarbazone derivative has 
afforded two new mononuclear structures, which in both 
cases, showed a good stability in solution and biological 
buffers. The compounds interact not only with DNA models 
(pBR322 and CT DNA) but also with protein (lysozyme and 
RNase models) showing different values of interaction and 
following a different pattern than cisplatin.  Both compounds 
caused cytotoxicity in a concentration- dependent manner on 
several tumor cell lines included leukemia and different solid 
tumors (lung and bone). The important pharmacological fact is 
that both compounds showed high selectivity for tumor cells 
and no activity versus healthy cells such as normal L929 
fibroblast.  
Moreover, the palladium complex 1 is not only endowed with 
a higher cytotoxicity than the platinum complex 2 but also with 
potent inhibition capacity of proteasome 20S. With these data 
on hand, we can establish that the mechanism of these 
complexes must be quite different to cisplatin. 
As a whole, these results indicate that compound, 1 is an 
interesting candidate for potential antitumor uses, and provide 
new insight into the development of palladium compounds as 
potential anticancer agents. 
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